drugset

drugset / Trial / NCT01028950

YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness

NCT01028950 ↗

Phase 3 Completed 52 enrolled Astellas Pharma Inc

NaSingle-groupOpen-labelPrevention

Summary

To evaluate the safety and efficacy of the oral dose of YM150 for prevention of venous thromboembolism (VTE) in patients with acute medical illness.

Timeline

Start: 2009-05
Primary completion: 2010-04
Completion: 2010-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	darexaban	Small molecule	—	Oral

Indications